Endogeneous remyelination: Findings in human studies

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 5, 2012, Pages 598-609

  Kipp, Markus ^a,b   Victor, Marion ^a   Martino, Gianvito ^c   Franklin, Robin J M ^d  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cuprizone; Multiple sclerosis; Oligodendrocytes; Regeneration; Remyelination; Repair

Indexed keywords

FINGOLIMOD; GAMMA INTERFERON; GLATIRAMER; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; AUTOPSY; BRAIN BIOPSY; BRAIN REGION; CELL MATURATION; CELL PROLIFERATION; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE DURATION; ENCEPHALITIS; GENDER; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; MYELIN SHEATH; NONHUMAN; OLIGODENDROGLIA; REMYELINIZATION; REVIEW; STEM CELL TRANSPLANTATION;

EID: 84863932287     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712801661257     Document Type: Review

References (133)

1. van der Valk, P.; De Groot, C.J. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol. Appl. Neurobiol., 2000, 26, 2-10.
2. Geurts, J.J.; Stys, P.K.; Minagar, A.; Amor, S.; Zivadinov, R. Gray matter pathology in (chronic) MS: modern views on an early observation. J. Neurol. Sci., 2009, 282, 12-20.
3. Geurts, J.J.; Barkhof, F. Grey matter pathology in multiple sclerosis. Lancet Neurol., 2008, 7, 841-851.
4. Back, S.A.; Tuohy, T.M.; Chen, H.; Wallingford, N.; Craig, A.; Struve, J.; Luo, N.L.; Banine, F.; Liu, Y.; Chang, A.; Trapp, B.D.; Bebo, B.F., Jr.; Rao, M.S.; Sherman, L.S. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat. Med., 2005, 11, 966-972.
5. Zawadzka, M.; Rivers, L.E.; Fancy, S.P.; Zhao, C.; Tripathi, R.; Jamen, F.; Young, K.; Goncharevich, A.; Pohl, H.; Rizzi, M.; Rowitch, D.H.; Kessaris, N.; Suter, U.; Richardson, W.D.; Franklin, R.J. CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. Cell Stem Cell, 2010, 6, 578-590.
6. Franklin, R.J.; Ffrench-Constant, C. Remyelination in the CNS: from biology to therapy. Nat. Rev. Neurosci., 2008, 9, 839-855.
7. Franklin, R.J. Why does remyelination fail in multiple sclerosis? Nat. Rev. Neurosci., 2002, 3, 705-714.
8. Perier, O.; Gregoire, A. Electron microscopic features of multiple sclerosis lesions. Brain, 1965, 88, 937-952.
9. Rodriguez, M.; Scheithauer, B. Ultrastructure of multiple sclerosis. Ultrastruct. Pathol., 1994, 18, 3-13.
10. Prineas, J.W.; Kwon, E.E.; Cho, E.S.; Sharer, L.R. Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques. Ann. NY Acad. Sci., 1984, 436, 11-32.
11. Prineas, J.W.; Connell, F. Remyelination in multiple sclerosis. Ann. Neurol., 1979, 5, 22-31.
12. Marik, C.; Felts, P.A.; Bauer, J.; Lassmann, H.; Smith, K.J. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain, 2007, 130, 2800-2815.
13. Halliday, A.M. Visual evoked potentials in demyelinating disease. Adv. Neurol., 1981, 31, 201-215.
14. Kornek, B.; Storch, M.K.; Weissert, R.; Wallstroem, E.; Stefferl, A.; Olsson, T.; Linington, C.; Schmidbauer, M.; Lassmann, H. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol., 2000, 157, 267-276.
15. Irvine, K.A.; Blakemore, W.F. Remyelination protects axons from demyelination-associated axon degeneration. Brain, 2008, 131, 1464-1477.
16. Pohl, H.B.; Porcheri, C.; Mueggler, T.; Bachmann, L.C.; Martino, G.; Riethmacher, D.; Franklin, R.J.; Rudin, M.; Suter, U. Genetically induced adult oligodendrocyte cell death is associated with poor myelin clearance, reduced remyelination, and axonal damage. J. Neurosci., 2011, 31, 1069-1080.
17. Duncan, I.D.; Brower, A.; Kondo, Y.; Curlee, J.F., Jr.; Schultz, R.D. Extensive remyelination of the CNS leads to functional recovery. Proc. Natl. Acad. Sci. USA, 2009, 106, 6832-6836.
18. Edgar, J.M.; Nave, K.A. The role of CNS glia in preserving axon function. Curr. Opin. Neurobiol., 2009, 19, 498-504.
19. Prineas, J.W.; Kwon, E.E.; Cho, E.S.; Sharer, L.R.; Barnett, M.H.; Oleszak, E.L.; Hoffman, B.; Morgan, B.P. Immunopathology of secondary-progressive multiple sclerosis. Ann. Neurol., 2001, 50, 646-657.
20. Mason, J.L.; Suzuki, K.; Chaplin, D.D.; Matsushima, G.K. Interleukin-1beta promotes repair of the CNS. J. Neurosci., 2001, 21, 7046-7052.
21. Acs, P.; Kipp, M.; Norkute, A.; Johann, S.; Clarner, T.; Braun, A.; Berente, Z.; Komoly, S.; Beyer, C. 17beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice. Glia, 2009, 57, 807-814.
22. Harsan, L.A.; Steibel, J.; Zaremba, A.; Agin, A.; Sapin, R.; Poulet, P.; Guignard, B.; Parizel, N.; Grucker, D.; Boehm, N.; Miller, R.H.; Ghandour, M.S. Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. J. Neurosci., 2008, 28, 14189-14201.
23. Kipp, M.; Beyer, C. Impact of sex steroids on neuroinflammatory processes and experimental multiple sclerosis. Front. Neuroendocrinol., 2009, 30, 188-200.
24. Huang, J.; Viswakarma, N.; Yu, S.; Jia, Y.; Bai, L.; Vluggens, A.; Cherkaoui-Malki, M.; Khan, M.; Singh, I.; Yang, G.; Rao, M.S.; Borensztajn, J.; Reddy, J.K. Progressive endoplasmic reticulum stress contributes to hepatocarcinogenesis in fatty acyl-CoA oxidase 1-deficient mice. Am. J. Pathol., 2011, 179, 703-713.
25. Charles, P.; Reynolds, R.; Seilhean, D.; Rougon, G.; Aigrot, M.S.; Niezgoda, A.; Zalc, B.; Lubetzki, C. Re-expression of PSA-NCAM by demyelinated axons: an inhibitor of remyelination in multiple sclerosis? Brain, 2002, 125, 1972-1979.
26. Mi, S.; Hu, B.; Hahm, K.; Luo, Y.; Kam Hui, E.S.; Yuan, Q.; Wong, W.M.; Wang, L.; Su, H.; Chu, T.H.; Guo, J.; Zhang, W.; So, K.F.; Pepinsky, B.; Shao, Z.; Graff, C.; Garber, E.; Jung, V.; Wu, E.X.; Wu, W. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med., 2007, 13, 1228-1233.
27. Kotter, M.R.; Li, W.W.; Zhao, C.; Franklin, R.J. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J. Neurosci., 2006, 26, 328-332.
28. Fancy, S.P.; Baranzini, S.E.; Zhao, C.; Yuk, D.I.; Irvine, K.A.; Kaing, S.; Sanai, N.; Franklin, R.J.; Rowitch, D.H. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev., 2009, 23, 1571-1585.
29. Fancy, S.P.; Harrington, E.P.; Yuen, T.J.; Silbereis, J.C.; Zhao, C.; Baranzini, S.E.; Bruce, C.C.; Otero, J.J.; Huang, E.J.; Nusse, R.; Franklin, R.J.; Rowitch, D.H. Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination. Nat. Neurosci., 2011, 14, 1009-1016.
30. Fancy, S.P.; Chan, J.R.; Baranzini, S.E.; Franklin, R.J.; Rowitch, D.H. Myelin regeneration: a recapitulation of development? Annu. Rev. Neurosci., 2011, 34, 21-43.
31. Fancy, S.P.; Kotter, M.R.; Harrington, E.P.; Huang, J.K.; Zhao, C.; Rowitch, D.H.; Franklin, R.J. Overcoming remyelination failure in multiple sclerosis and other myelin disorders. Exp. Neurol., 2010, 225, 18-23.
32. Garay, L.; Gonzalez Deniselle, M.C.; Gierman, L.; Meyer, M.; Lima, A.; Roig, P.; De Nicola, A.F. Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Neuroimmunomodulation, 2008, 15, 76-83.
33. Kipp, M.; Gingele, S.; Pott, F.; Clarner, T.; van der Valk, P.; Denecke, B.; Gan, L.; Siffrin, V.; Zipp, F.; Dreher, W.; Baumgartner, W.; Pfeifenbring, S.; Godbout, R.; Amor, S.; Beyer, C. BLBP-expression in astrocytes during experimental demyelination and in human multiple sclerosis lesions. Brain Behav. Immun., 2011, 25(8), 1554-1568.
34. Pott, F.; Gingele, S.; Clarner, T.; Dang, J.; Baumgartner, W.; Beyer, C.; Kipp, M. Cuprizone effect on myelination, astrogliosis and microglia attraction in the mouse basal ganglia. Brain Res., 2009, 1305, 137-149.
35. Stidworthy, M.F.; Genoud, S.; Suter, U.; Mantei, N.; Franklin, R.J. Quantifying the early stages of remyelination following cuprizoneinduced demyelination. Brain Pathol., 2003, 13, 329-339.
36. Skihar, V.; Silva, C.; Chojnacki, A.; Doring, A.; Stallcup, W.B.; Weiss, S.; Yong, V.W. Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate. Proc. Natl. Acad. Sci. USA, 2009, 106, 17992-17997.
37. Woodruff, R.H.; Franklin, R.J. Demyelination and remyelination of the caudal cerebellar peduncle of adult rats following stereotaxic injections of lysolecithin, ethidium bromide, and complement/antigalactocerebroside: a comparative study. Glia, 1999, 25, 216-228.
38. Clarner, T.; Parabucki, A.; Beyer, C.; Kipp, M. Corticosteroids impair remyelination in the corpus callosum of cuprizone-treated mice. J. Neuroendocrinol., 2011, 23(7), 601-611.
39. Arnett, H.A.; Wang, Y.; Matsushima, G.K.; Suzuki, K.; Ting, J.P. Functional genomic analysis of remyelination reveals importance of inflammation in oligodendrocyte regeneration. J. Neurosci., 2003, 23, 9824-9832.
40. Patrikios, P.; Stadelmann, C.; Kutzelnigg, A.; Rauschka, H.; Schmidbauer, M.; Laursen, H.; Sorensen, P.S.; Bruck, W.; Lucchinetti, C.; Lassmann, H. Remyelination is extensive in a subset of multiple sclerosis patients. Brain, 2006, 129, 3165-3172.
41. Barkhof, F.; Bruck, W.; De Groot, C.J.; Bergers, E.; Hulshof, S.; Geurts, J.; Polman, C.H.; van der Valk, P. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch. Neurol., 2003, 60, 1073-1081.
42. Albert, M.; Antel, J.; Bruck, W.; Stadelmann, C. Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathol., 2007, 17, 129-138.
43. Patani, R.; Balaratnam, M.; Vora, A.; Reynolds, R. Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropathol. Appl. Neurobiol., 2007, 33, 277-287.
44. Coman, I.; Aigrot, M.S.; Seilhean, D.; Reynolds, R.; Girault, J.A.; Zalc, B.; Lubetzki, C. Nodal, paranodal and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis. Brain, 2006, 129, 3186-3195.
45. Saadat, L.; Dupree, J.L.; Kilkus, J.; Han, X.; Traka, M.; Proia, R.L.; Dawson, G.; Popko, B. Absence of oligodendroglial glucosylceramide synthesis does not result in CNS myelin abnormalities or alter the dysmyelinating phenotype of CGTdeficient mice. Glia, 2010, 58, 391-398.
46. Sasaki, M.; Black, J.A.; Lankford, K.L.; Tokuno, H.A.; Waxman, S.G.; Kocsis, J.D. Molecular reconstruction of nodes of Ranvier after remyelination by transplanted olfactory ensheathing cells in the demyelinated spinal cord. J. Neurosci., 2006, 26, 1803-1812.
47. Hildebrand, C.; Hahn, R. Relation between myelin sheath thickness and axon size in spinal cord white matter of some vertebrate species, J. Neurol. Sci., 1978, 38, 421-434.
48. Ozawa, K.; Suchanek, G.; Breitschopf, H.; Bruck, W.; Budka, H.; Jellinger, K.; Lassmann, H. Patterns of oligodendroglia pathology in multiple sclerosis. Brain, 1994, 117, 1311-1322.
49. Kipp, M.; Clarner, C.; Gingele, S.; Pott, F.; Amor, S.; van der Valk, P.; Beyer, C. Brain lipid binding protein (FABP7) as modulator of astrocyte function. Physiol. Res., 2011, 60(Suppl. 1), S49-S60.
50. Goldschmidt, T.; Antel, J.; Konig, F.B.; Bruck, W.; Kuhlmann, T. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology, 2009, 72, 1914-1921.
51. Barnett, M.H.; Prineas, J.W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol., 2004, 55, 458-468.
52. Ibanez, C.; Shields, S.A.; El-Etr, M.; Baulieu, E.E.; Schumacher, M.; Franklin, R.J. Systemic progesterone administration results in a partial reversal of the age-associated decline in CNS remyelination following toxin-induced demyelination in male rats. Neuropathol. Appl. Neurobiol., 2004, 30, 80-89.
53. Shields, S.A.; Gilson, J.M.; Blakemore, W.F.; Franklin, R.J. Remyelination occurs as extensively but more slowly in old rats compared to young rats following gliotoxin-induced CNS demyelination. Glia, 1999, 28, 77-83.
54. Gilson, J.; Blakemore, W.F. Failure of remyelination in areas of demyelination produced in the spinal cord of old rats. Neuropathol. Appl. Neurobiol., 1993, 19, 173-181.
55. Sim, F.J.; Zhao, C.; Penderis, J.; Franklin, R.J. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J. Neurosci., 2002, 22, 2451-2459.
56. Shen, S.; Sandoval, J.; Swiss, V.A.; Li, J.; Dupree, J.; Franklin, R.J.; Casaccia-Bonnefil, P. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat. Neurosci., 2008, 11, 1024-1034.
57. Hinks, G.L.; Franklin, R.J. Delayed changes in growth factor gene expression during slow remyelination in the CNS of aged rats. Mol. Cell Neurosci., 2000, 16, 542-556.
58. Prineas, J.W.; Barnard, R.O.; Kwon, E.E.; Sharer, L.R.; Cho, E.S. Multiple sclerosis: remyelination of nascent lesions. Ann. Neurol., 1993, 33, 137-151.
59. Raine, C.S.; Wu, E. Multiple sclerosis: remyelination in acute lesions. J. Neuropathol. Exp. Neurol., 1993, 52, 199-204.
60. Kipp, M.; Norkute, A.; Johann, S.; Lorenz, L.; Braun, A.; Hieble, A.; Gingele, S.; Pott, F.; Richter, J.; Beyer, C. Brain-region-specific astroglial responses in vitro after LPS exposure. J. Mol. Neurosci., 2008, 35, 235-243.
61. Pintado, C.; Revilla, E.; Vizuete, M.L.; Jimenez, S.; Garcia-Cuervo, L.; Vitorica, J.; Ruano, D.; Castano, A. Regional difference in inflammatory response to LPS-injection in the brain: Role of microglia cell density. J. Neuroimmunol., 2011, 238(1-2), 44-51.
62. Luyt, K.; Slade, T.P.; Dorward, J.J.; Durant, C.F.; Wu, Y.; Shigemoto, R.; Mundell, S.J.; Varadi, A.; Molnar, E. Developing oligodendrocytes express functional GABA(B) receptors that stimulate cell proliferation and migration. J. Neurochem., 2007, 100, 822-840.
63. Stevens, B.; Porta, S.; Haak, L.L.; Gallo, V.; Fields, R.D. Adenosine: a neuron-glial transmitter promoting myelination in the CNS in response to action potentials. Neuron, 2002, 36, 855-868.
64. Barres, B.A.; Raff, M.C. Proliferation of oligodendrocyte precursor cells depends on electrical activity in axons. Nature, 1993, 361, 258-260.
65. Greer, J.M.; McCombe, P.A. Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J. Neuroimmunol., 2011, 234, 7-18.
66. Sellner, J.; Kraus, J.; Awad, A.; Milo, R.; Hemmer, B.; Stuve, O. The increasing incidence and prevalence of female multiple sclerosis--a critical analysis of potential environmental factors. Autoimmun. Rev., 2011, 10, 495-502.
67. Kipp, M.; Berger, K.; Clarner, T.; Dang, J.; Beyer, C. Sex steroids control neuroinflammatory processes in the brain: relevance for acute ischemia and degenerative demyelination. J. Neuroendocrinol., 2012, 24(1), 62-70.
68. Vukusic, S.; Ionescu, I.; El-Etr, M.; Schumacher, M.; Baulieu, E.E.; Cornu, C.; Confavreux, C. The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement. J. Neurol. Sci., 2009, 286, 114-118.
69. Confavreux, C.; Hutchinson, M.; Hours, M.M.; Cortinovis-Tourniaire, P.; Moreau, T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med., 1998, 339, 285-291.
70. Voskuhl, R.R. Hormone-based therapies in MS. Int. MS J., 2003, 10, 60-66.
71. Gold, S.M.; Voskuhl, R.R. Estrogen and testosterone therapies in multiple sclerosis. Prog. Brain Res., 2009, 175, 239-251.
72. Li, W.W.; Penderis, J.; Zhao, C.; Schumacher, M.; Franklin, R.J. Females remyelinate more efficiently than males following demyelination in the aged but not young adult. CNS Exp. Neurol., 2006, 202, 250-254.
73. Crawford, D.K.; Mangiardi, M.; Song, B.; Patel, R.; Du, S.; Sofroniew, M.V.; Voskuhl, R.R.; Tiwari-Woodruff, S.K. Oestrogen receptor beta ligand: a novel treatment to enhance endogenous functional remyelination. Brain, 2010, 133, 2999-3016.
74. Zhu, T.S.; Glaser, M. Neuroprotection and enhancement of remyelination by estradiol and dexamethasone in cocultures of rat DRG neurons and Schwann cells. Brain Res., 2008, 1206, 20-32.
75. Hussain, R.; El-Etr, M.; Gaci, O.; Jennifer, R.; Macklin, W.B.; Kumar, N.; Sitruk-Ware, R.; Schumacher, M.; Ghoumari, A.M. Progesterone and Nestorone Facilitate Axon Remyelination: A Role for Progesterone Receptors. Endocrinology, 2011, 152(10), 3820-3831.
76. Prineas, J.W.; Kwon, E.E.; Goldenberg, P.Z.; Ilyas, A.A.; Quarles, R.H.; Benjamins, J.A.; Sprinkle, T.J. Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. Lab. Invest., 1989, 61, 489-503.
77. Ghatak, N.R.; Leshner, R.T.; Price, A.C.; Felton, W.L., 3rd. Remyelination in the human central nervous system. J. Neuropathol. Exp. Neurol., 1989, 48, 507-518.
78. Kerschensteiner, M.; Gallmeier, E.; Behrens, L.; Leal, V.V.; Misgeld, T.; Klinkert, W.E.; Kolbeck, R.; Hoppe, E.; Oropeza-Wekerle, R.L.; Bartke, I.; Stadelmann, C.; Lassmann, H.; Wekerle, H.; Hohlfeld, R. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J. Exp. Med., 1999, 189, 865-870.
79. Hinks, G.L.; Franklin, R.J. Distinctive patterns of PDGF-A, FGF-2, IGF-I, and TGF-beta1 gene expression during remyelination of experimentally-induced spinal cord demyelination. Mol. Cell Neurosci., 1999, 14, 153-168.
80. Johnson, E.S.; Ludwin, S.K. The demonstration of recurrent demyelination and remyelination of axons in the central nervous system. Acta Neuropathol., 1981, 53, 93-98.
81. Kotter, M.R.; Setzu, A.; Sim, F.J.; Van Rooijen, N.; Franklin, R.J. Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia, 2001, 35, 204-212.
82. Taoufik, E.; Tseveleki, V.; Chu, S.Y.; Tselios, T.; Karin, M.; Lassmann, H.; Szymkowski, D.E.; Probert, L. Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB. Brain, 2011, 134, 2722-2735.
83. Brambilla, R.; Ashbaugh, J.J.; Magliozzi, R.; Dellarole, A.; Karmally, S.; Szymkowski, D.E.; Bethea, J.R. Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain, 2011, 134, 2736-2754.
84. Njenga, M.K.; Murray, P.D.; McGavern, D.; Lin, X.; Drescher, K.M.; Rodriguez, M. Absence of spontaneous central nervous system remyelination in class II-deficient mice infected with Theiler's virus. J. Neuropathol. Exp. Neurol., 1999, 58, 78-91.
85. Biancotti, J.C.; Kumar, S.; de Vellis, J. Activation of inflammatory response by a combination of growth factors in cuprizone-induced demyelinated brain leads to myelin repair. Neurochem. Res., 2008, 33, 2615-2628.
86. Barcellos, L.F.; Sawcer, S.; Ramsay, P.P.; Baranzini, S.E.; Thomson, G.; Briggs, F.; Cree, B.C.; Begovich, A.B.; Villoslada, P.; Montalban, X.; Uccelli, A.; Savettieri, G.; Lincoln, R.R.; DeLoa, C.; Haines, J.L.; Pericak-Vance, M.A.; Compston, A.; Hauser, S.L.; Oksenberg, J.R. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum. Mol. Genet., 2006, 15, 2813-2824.
87. Mana, P.; Linares, D.; Fordham, S.; Staykova, M.; Willenborg, D. Deleterious role of IFNgamma in a toxic model of central nervous system demyelination. Am. J. Pathol., 2006, 168, 1464-1473.
88. Keirstead, H.S.; Levine, J.M.; Blakemore, W.F. Response of the oligodendrocyte progenitor cell population (defined by NG2 labelling) to demyelination of the adult spinal cord. Glia, 1998, 22, 161-170.
89. Penderis, J.; Shields, S.A.; Franklin, R.J. Impaired remyelination and depletion of oligodendrocyte progenitors does not occur following repeated episodes of focal demyelination in the rat central nervous system, Brain, 2003, 126, 1382-1391.
90. Blakemore, W.F.; Chari, D.F.; Gilson, J.M.; Crang, A.J. Modelling large areas of demyelination in the rat reveals the potential and possible limitations of transplanted glial cells for remyelination in the CNS. Glia, 2002, 38, 155-168.
91. Blakemore, W.F.; Gilson, J.M.; Crang, A.J. Transplanted glial cells migrate over a greater distance and remyelinate demyelinated lesions more rapidly than endogenous remyelinating cells. J. Neurosci. Res., 2000, 61, 288-294.
92. Scolding, N.; Franklin, R.; Stevens, S.; Heldin, C.H.; Compston, A.; Newcombe, J. Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. Brain, 1998, 121(12), 2221-2228.
93. Syed, Y.A.; Hand, E.; Mobius, W.; Zhao, C.; Hofer, M.; Nave, K.A.; Kotter, M.R.; Inhibition of CNS remyelination by the presence of semaphorin 3A. J. Neurosci., 2011, 31, 3719-3728.
94. Sloane, J.A.; Batt, C.; Ma, Y.; Harris, Z.M.; Trapp, B.; Vartanian, T. Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. Proc. Natl. Acad. Sci. USA, 2010, 107, 11555-11560.
95. Manrique-Hoyos, N.; Jurgens, T.; Gronborg, M.; Kreutzfeldt, M.; Schedensack, M.; Kuhlmann, T.; Schrick, C.; Bruck, W.; Urlaub, H.; Simons, M.; Merkler, D. Late motor decline after accomplished remyelination: impact for progressive multiple sclerosis. Ann. Neurol., 2012, 71, 227-244.
96. Mahad, D.; Callahan, M.K.; Williams, K.A.; Ubogu, E.E.; Kivisakk, P.; Tucky, B.; Kidd, G.; Kingsbury, G.A.; Chang, A.; Fox, R.J.; Mack, M.; Sniderman, M.B.; Ravid, R.; Staugaitis, S.M.; Stins, M.F.; Ransohoff, R.M. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain, 2006, 129, 212-223.
97. Prineas, J.W.; Barnard, R.O.; Revesz, T.; Kwon, E.E.; Sharer, L.; Cho, E.S. Multiple sclerosis. Pathology of recurrent lesions. Brain, 1993, 116(Pt 3), 681-693.
98. Pringle, N.P.; Mudhar, H.S.; Collarini, E.J.; Richardson, W.D. PDGF receptors in the rat CNS: during late neurogenesis, PDGF alpha-receptor expression appears to be restricted to glial cells of the oligodendrocyte lineage. Development, 1992, 115, 535-551.
99. Ellison, J.A.; de Vellis, J. Platelet-derived growth factor receptor is expressed by cells in the early oligodendrocyte lineage. J. Neurosci. Res., 1994, 37, 116-128.
100. Butt, A.M.; Hornby, M.F.; Ibrahim, M.; Kirvell, S.; Graham, A.; Berry, M. PDGF-alpha receptor and myelin basic protein mRNAs are not coexpressed by oligodendrocytes in vivo: a double in situ hybridization study in the anterior medullary velum of the neonatal rat. Mol. Cell Neurosci., 1997, 8, 311-322.
101. Maeda, Y.; Solanky, M.; Menonna, J.; Chapin, J.; Li, W.; Dowling, P. Platelet-derived growth factor-alpha receptor-positive oligodendroglia are frequent in multiple sclerosis lesions. Ann. Neurol., 2001, 49, 776-785.
102. Robel, S.; Berninger, B.; Gotz, M. The stem cell potential of glia: lessons from reactive gliosis. Nat. Rev. Neurosci., 2011, 12, 88-104.
103. Nishiyama, A.; Chang, A.; Trapp, B.D. NG2+ glial cells: a novel glial cell population in the adult brain. J. Neuropathol. Exp. Neurol., 1999, 58, 1113-1124.
104. Monje, M.L.; Toda, H.; Palmer, T.D. Inflammatory blockade restores adult hippocampal neurogenesis. Science, 2003, 302, 1760-1765.
105. Jessell, T.M.; Dodd, J. Floor plate-derived signals and the control of neural cell pattern in vertebrates. Harvey Lect., 1990, 86, 87-128.
106. Seifert, T.; Bauer, J.; Weissert, R.; Fazekas, F.; Storch, M.K. Differential expression of sonic hedgehog immunoreactivity during lesion evolution in autoimmune encephalomyelitis. J. Neuropathol. Exp. Neurol., 2005, 64, 404-411.
107. Irvin, D.K.; Nakano, I.; Paucar, A.; Kornblum, H.I. Patterns of Jagged1, Jagged2, Delta-like 1 and Delta-like 3 expression during late embryonic and postnatal brain development suggest multiple functional roles in progenitors and differentiated cells. J. Neurosci. Res., 2004, 75, 330-343.
108. Johns, T.G.; Bernard, C.C. The structure and function of myelin oligodendrocyte glycoprotein. J. Neurochem., 1999, 72, 1-9.
109. Pluchino, S.; Zanotti, L.; Rossi, B.; Brambilla, E.; Ottoboni, L.; Salani, G.; Martinello, M.; Cattalini, A.; Bergami, A.; Furlan, R.; Comi, G.; Constantin, G.; Martino, G. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature, 2005, 436, 266-271.
110. Pluchino, S.; Muzio, L.; Imitola, J.; Deleidi, M.; Alfaro-Cervello, C.; Salani, G.; Porcheri, C.; Brambilla, E.; Cavasinni, F.; Bergamaschi, A.; Garcia-Verdugo, J.M.; Comi, G.; Khoury, S.J.; Martino, G. Persistent inflammation alters the function of the endogenous brain stem cell compartment. Brain, 2008, 131, 2564-2578.
111. Muzio, L.; Cavasinni, F.; Marinaro, C.; Bergamaschi, A.; Bergami, A.; Porcheri, C.; Cerri, F.; Dina, G.; Quattrini, A.; Comi, G.; Furlan, R.; Martino, G. Cxcl10 enhances blood cells migration in the sub-ventricular zone of mice affected by experimental autoimmune encephalomyelitis. Mol. Cell Neurosci., 2009, 43, 268-280.
112. Franklin, R.J.; Blakemore, W.F. To what extent is oligodendrocyte progenitor migration a limiting factor in the remyelination of multiple sclerosis lesions? Mult. Scler., 1997, 3, 84-87.
113. Franklin, R.J. Remyelination of the demyelinated CNS: the case for and against transplantation of central, peripheral and olfactory glia. Brain Res. Bull., 2002, 57, 827-832.
114. Pluchino, S.; Quattrini, A.; Brambilla, E.; Gritti, A.; Salani, G.; Dina, G.; Galli, R.; Del Carro, U.; Amadio, S.; Bergami, A.; Furlan, R.; Comi, G.; Vescovi, A.L.; Martino, G. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature, 2003, 422, 688-694.
115. Zappia, E.; Casazza, S.; Pedemonte, E.; Benvenuto, F.; Bonanni, I.; Gerdoni, E.; Giunti, D.; Ceravolo, A.; Cazzanti, F.; Frassoni, F.; Mancardi, G.; Uccelli, A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood, 2005, 106, 1755-1761.
116. Pluchino, S.; Gritti, A.; Blezer, E.; Amadio, S.; Brambilla, E.; Borsellino, G.; Cossetti, C.; Del Carro, U.; Comi, G.; Hart, B.T.; Vescovi, A.; Martino, G. Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates. Ann. Neurol., 2009, 66, 343-354.
117. Aharoni, R.; Herschkovitz, A.; Eilam, R.; Blumberg-Hazan, M.; Sela, M.; Bruck, W.; Arnon, R. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA, 2008, 105, 11358-11363.
118. Brinkmann, V.; Davis, M.D.; Heise, C.E.; Albert, R.; Cottens, S.; Hof, R.; Bruns, C.; Prieschl, E.; Baumruker, T.; Hiestand, P.; Foster, C.A.; Zollinger, M.; Lynch, K.R. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem., 2002, 277, 21453-21457.
119. Foster, C.A.; Howard, L.M.; Schweitzer, A.; Persohn, E.; Hiestand, P.C.; Balatoni, B.; Reuschel, R.; Beerli, C.; Schwartz, M.; Billich, A. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J. Pharmacol. Exp. Ther., 2007, 323, 469-475.
120. Antel, J.P.; Miron, V.E. Central nervous system effects of current and emerging multiple sclerosis-directed immuno-therapies. Clin. Neurol. Neurosurg., 2008, 110, 951-957.
121. Coelho, R.P.; Payne, S.G.; Bittman, R.; Spiegel, S.; Sato-Bigbee, C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J. Pharmacol. Exp. Ther., 2007, 323, 626-635.
122. Jung, C.G.; Kim, H.J.; Miron, V.E.; Cook, S.; Kennedy, T.E.; Foster, C.A.; Antel, J.P.; Soliven, B. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia, 2007, 55, 1656-1667.
123. Miron, V.E.; Jung, C.G.; Kim, H.J.; Kennedy, T.E.; Soliven, B.; Antel, J.P. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann. Neurol., 2008, 63, 61-71.
124. Miron, V.E.; Ludwin, S.K.; Darlington, P.J.; Jarjour, A.A.; Soliven, B.; Kennedy, T.E.; Antel, J.P. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am. J. Pathol., 2010, 176, 2682-2694.
125. Kim, S.; Steelman, A.J.; Koito, H.; Li, J. Astrocytes promote TNFmediated toxicity to oligodendrocyte precursors. J. Neurochem., 2011, 116, 53-66.
126. Skripuletz, T.; Lindner, M.; Kotsiari, A.; Garde, N.; Fokuhl, J.; Linsmeier, F.; Trebst, C.; Stangel, M. Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am. J. Pathol., 2008, 172, 1053-1061.
127. Arnold, D.L. Evidence for neuroprotection and remyelination using imaging techniques. Neurology, 2007, 68, S83-S90; discussion S91-96.
128. Dousset, V.; Gayou, A.; Brochet, B.; Caille, J.M. Early structural changes in acute MS lesions assessed by serial magnetization transfer studies. Neurology, 1998, 51, 1150-1155.
129. Bitsch, A.; Kuhlmann, T.; Stadelmann, C.; Lassmann, H.; Lucchinetti, C.; Bruck, W. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann. Neurol., 2001, 49, 793-796.
130. Deloire-Grassin, M.S.; Brochet, B.; Quesson, B.; Delalande, C.; Dousset, V.; Canioni, P.; Petry, K.G. In vivo evaluation of remyelination in rat brain by magnetization transfer imaging. J. Neurol. Sci., 2000, 178, 10-16.
131. Wang, C.; Wu, C.; Popescu, D.C.; Zhu, J.; Macklin, W.B.; Miller, R.H.; Wang, Y. Longitudinal near-infrared imaging of myelination. J. Neurosci., 2011, 31, 2382-2390.
132. Nait-Oumesmar, B.; Picard-Riera, N.; Kerninon, C.; Decker, L.; Seilhean, D.; Hoglinger, G.U.; Hirsch, E.C.; Reynolds, R.; Baron-Van Evercooren, A. Activation of the subventricular zone in multiple sclerosis: evidence for early glial progenitors. Proc. Natl. Acad. Sci. USA, 2007, 104, 4694-4699.
133. Nait-Oumesmar, B.; Picard-Riera, N.; Kerninon, C.; Baron-Van Evercooren, A. The role of SVZ-derived neural precursors in demyelinating diseases: from animal models to multiple sclerosis. J. Neurol. Sci., 2008, 265, 26-31.